1 / 8

Description of Each Study in the Cross Trial Safety Analysis

Description of Each Study in the Cross Trial Safety Analysis. Solomon SD, et al. Circulation 2008 [Epub Mar 31]. Common Baseline Characteristics Across Trials. Solomon SD, et al. Circulation 2008 [Epub Mar 31].

zizi
Download Presentation

Description of Each Study in the Cross Trial Safety Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

  2. Common Baseline Characteristics Across Trials Solomon SD, et al. Circulation 2008 [Epub Mar 31]

  3. Event Rates per 1000 Patient-Years and Pooled Hazard Ratios With 95% CIs for the Principal Composite End Point of Cardiovascular Death, Myocardial Infarction, Stroke, Heart Failure, or Thromboembolism for Each Individual Trial, for Each Dose Regimen, and for All the Trials Combined, Adjusted for Baseline Cardiovascular Risk Solomon SD, et al. Circulation 2008 [Epub Mar 31]

  4. Kaplan–Meier curves for individual trials in analysis Note that CDME had too few events to plot Solomon SD, et al. Circulation 2008 [Epub Mar 31]

  5. Overall Pooled Event Rates for the Hierarchy of Events, Adjusted for Baseline Cardiovascular Risk Solomon SD, et al. Circulation 2008 [Epub Mar 31]

  6. Hazard ratios for each dose regimen and the combined overall hazard ratio with 95% CIs Solomon SD, et al. Circulation 2008 [Epub Mar 31]

  7. Relationship between celecoxib dose, baseline cardiovascular risk, and the principal combined outcome of cardiovascular death, myocardial infarction, stroke, heart failure, or thromboembolic event Solomon SD, et al. Circulation 2008 [Epub Mar 31]

  8. Clinical perspective Solomon SD, et al. Circulation 2008 [Epub Mar 31]

More Related